SIXTY-EIGHTH

ANNUAL MEETING

November 20–24, 2019 | astmh.org | ajtmh.org | #TropMed19 #iamTropMed

GAYLORD NATIONAL RESORT AND CONVENTION CENTER | NATIONAL HARBOR, MARYLAND, USA

ABSTRACT BOOK

ASTMH is an international society committed to equity and global impact through the treatment and prevention of tropical infections diseases. Our diverse membership comes from more than 115 countries... we are committed to the open exchange of ideas, freedom of thought and expression, and productive scientific debate in a open and diverse environment that is built on dignity and mutual respect for all. There is no discrimination based on personal attributes including but not limited to ethnicity, color, national origin, age, religion, socioeconomic status, disability, sexual orientation, gender, and gender identity or expression.

Supplement to
The American Journal of Tropical Medicine and Hygiene
abstracts, 226 articles were selected for final review. 50 publications were specific for OWCL, 5 publications discussed wound care in both OWCL, and New World Cutaneous Leishmaniasis, and 58 publications were review articles. Study characteristics including number of participants, wound care strategy/ intervention (debridement and removal of crusts, occlusive dressings, cream/ointment containing silver, washing, topical antimicrobials), outcomes (cure, time to reepithelialization, induration reduction, scar formation-quality and cosmesis, safety/tolerability, costs, feasibility/accessibility), study location, and species identification, will be extracted from all eligible studies and analyzed. We will systematically map the literature and synthesize the current state of knowledge and topical wound-oriented management practices in OWCL in order to inform optimal adjunctive clinical approaches and guidelines. We will also identify knowledge gaps and potential prospective research questions to fill them.

1845

A SYSTEMATIC REVIEW OF WOUND CARE IN THE MANAGEMENT OF NEW WORLD CUTANEOUS LEISHMANIASIS

Ruwanthi Kariyawasam1, David Harris*, Christian Lecce1, Avinash N. Mukkala1, Evan Bebryc, Andrea K. Boggs1
1Institute of Medical Sciences, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Tropical Disease Unit, Toronto General Hospital and University of Toronto, Toronto, ON, Canada

New world cutaneous leishmaniasis (NWCL) typically presents as one or several chronic, infiltrative lesions on exposed parts of the body, and is treated pharmacologically to accelerate cure, reduce scarring, and to prevent parasite dissemination or relapse. Limited data support the role of local wound care for the management of NWCL, though the scope of such benefit and to which patient populations wound care should be applied remains underdetermined due to the absence of synthesized data on the subject. We aim to synthesize the literature around the role of wound care in the management of NWCL to inform treatment guidelines and evidence-based therapeutic strategies. Medline (Ovid), Embase (Ovid), and Pubmed (NCBI) were searched from inception to February 2019 without language restriction using combinations of the search terms “leishmania” and “wound care”. The GRADE approach will be used to assess quality of studies reporting specific wound care interventions. 626 articles were identified with the initial search. After screening titles and abstracts, 226 articles were selected for final review. 113 publications were specific for NWCL, 5 publications discussed wound care in both NWCL and Old World Cutaneous Leishmaniasis, and 58 publications were review articles. Study characteristics including number of participants, wound care strategy/ intervention (debridement and removal of crusts, occlusive dressings, cream/ointment containing silver, washing, topical antimicrobials), outcomes (cure, time to reepithelialization, induration reduction, scar formation-quality and cosmesis, safety/tolerability, costs, feasibility/accessibility), study location, and species identification, will be extracted from all eligible studies and analyzed. We will systematically map the literature and synthesize the current state of knowledge and topical wound-oriented management practices in NWCL in order to inform optimal adjunctive clinical approaches and guidelines. We will also identify knowledge gaps and potential prospective research questions to fill them.

1846

PHENOTYPIC CHARACTERIZATION OF TRYPANOSOMES CELLS TREATED WITH TETRACYCLIC IRRIDOIDS, ML F52 SUPPRESSION OF FLAGELLA ATTACHMENT PROTEINS

Georgina I. Djameh1, Thelma Tetteh1, Takuhiro Uto2, Frederick Ayerette1, Michael Arood Bosompem1, Faustus I. Azerigiyik3, Kofi D. Kwofe1, Tomoe Ohta1, Irene Ayi1, Shiro Iwanaga4, Nobuo Ohta1, Yukihiro Shoyama1, Mitsuok Ohashi1
1Noguchi Memorial Institute for Medical Research, Accra, Ghana, 2Nagasaki International University, Nagasaki, Japan, 3Centre for Plant Medicine Research, Mambong-Kaupam, Ghana, 4Tokyo Medical and Dental University, Tokyo, Japan

Despite the recent advances in drug research, finding a safe, effective, and easy to use chemotherapy for Human African Trypanosomiasis (HAT) remains a challenging task. This condition underlines the urgent necessity for the development of new drugs for the treatment of HAT. We previously identified the anti-trypanosome activities of three novel tetracyclic iridoids, ML-2-3, Molucin and ML-F52, isolated from Morinda lucida with I50 values of 3.75μM, 1.27μM and 0.43μM, respectively. Immunohistochemistry (IHC) study showed that the compounds significantly suppressed the expression of PfPR-2, which proceeded to the events of cell cycle alteration and apoptosis induction. Scanning Electron Microscopy revealed the severe phenotype of the flagella detached from the body of the parasite. Here we present a phenotypic characterization of ML-F52 treated trypanosomes in detail with analyzing the expression levels of Flagellum Attachment Zone (FAZ) filament proteins, Coiled-coil 2-domain containing protein (CC2D2) and Flagella Attachment Zone protein 1 (FAZ-1) by IHC and Western blot assays. Immunohistochemistry study showed that ML-F52 significantly suppressed the expression of CC2D2 after 12 hours of post treatment whilst FAZ-1 did not show any significant suppression. After 24 hours of post treatment, cell length and FAZ length decreased with the emergence of cell containing detached flagella as compared to the control. Also, ML-F52 caused multinucleated phenotype and an increase in number of cells with only one or no visible kinetoplast. Western blot assay showed that CC2D2 expression was reduced more than approximately 80% by 12 hours post treatment and approximately 80% by 24 hours post treatment. Our findings suggested that ML-F52 might significantly inhibit the development and function of the flagellum.

1847

VISCERAL LEISHMANIASIS ELISA TESTING: EVALUATION OF SERIAL SERUM SAMPLES REVEALS AN UNANTICIPATED FINDING

Naomi E. Aronson1, Nancy Koles*, Saule Nurmukhambetova1, Rupal Mody1, Edgie Mark Co1, Dutchabong Shaw2, Robert DeFratres1, Ines Lakhal-Naouar3
1Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 2William Beaumont Army Medical Center, El Paso, TX, United States, 3Walter Reed National Military Medical Center, Bethesda, MD, United States

Serologic testing for visceral leishmaniasis (VL) includes ELISA and immunochromatographic testing (ICT) methods. Generally antibody responses are reported to wane with time. 200 Iraq-deployed, healthy US servicemembers were enrolled in an asymptomatic VL surveillance study 2015-17 and ELISA testing of current, pre and post deployment sera was conducted. Their prior banked samples were requested from the Department of Defense Serum Repository; timepoints included entry to military service (accession), before deployment and upon return from Iraq. Serologic testing included a soluble Leishmania antigen-based ELISA using 1:400 sera dilution with positive ELISA results confirmed using a Leishmania Western Blot (WB, LDBios, France). Additionally, post Iraq and enrollment sera were tested with rk39 ICT (Kalazar Detect, Inbios WA). Enrollment sera from seven subjects tested positive on ELISA (3.5%) with one WB confirmed; there were no reactive rk39 serologies. Post-deployment sera tested ELISA positive in 55 subjects (27.5%), 48%